Dysbiosis of the Beneficial Gut Bacteria in Patients with Parkinson's Disease from IndiaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized the gut microbiota of Parkinson's disease patients in a South Indian population, a group not previously examined. Researchers used full-length 16S rRNA gene sequencing on an Oxford Nanopore platform. Long-read sequencing gives higher taxonomic accuracy than the short-read methods used in most prior Parkinson's studies. They compared cases and controls on alpha and beta diversity, ran LEfSe and random forest to find candidate biomarkers, and correlated taxa with functional constipation using Rome IV criteria.
Who was studied?
The case-control study enrolled 36 people from a tertiary hospital in coastal Karnataka, India: 23 Parkinson's patients and 13 healthy controls. Controls were mostly spouses, to match diet. Mean age was 60 years for patients and 56 for controls. Patients were staged with modified Hoehn and Yahr, mean 1.8, and 56.5% had functional constipation. Exclusions included secondary parkinsonism, primary gastrointestinal disease, and antibiotics within the prior month. All subjects ate a carbohydrate-rich mixed diet with no unusual restrictions.
What were the most important findings?
Patients and controls differed significantly in alpha diversity (Shannon P = 0.03, Simpson P = 0.02) and beta diversity. At the family level, Parkinson's cases had more Christensenellaceae and Oscillospiraceae and less Lachnospiraceae and Coriobacteriaceae. Cases showed higher Clostridia UCG-014, a group not previously linked to Parkinson's. Short-chain fatty acid producers were reduced, including Blautia, Faecalibacterium, Fusicatenibacter, and Collinsella. Among patients with constipation, Lachnospiraceae NK4A136 group, Dialister, Akkermansia, and Bacteroides were more abundant. These correlated with Rome IV constipation criteria.
What are the greatest implications of this study?
The findings extend the recurring pattern of Parkinson's gut dysbiosis to an Indian population, reinforcing that reduced short-chain fatty acid producers is a robust cross-population signal. Low producers of these fatty acids may weaken the gut barrier and promote inflammation. The novel enrichment of Clostridia UCG-014 offers a fresh candidate for future work. This is a small, single-site, cross-sectional study that cannot establish causation or function. The authors call for larger multi-site cohorts and longitudinal follow-up across Parkinson's subtypes.